Abstract
Migrastatin, a macrolide natural product, and its structurally related analogs are potent inhibitors of cancer cell metastasis, invasion and migration. In the present work, a specialized fragment-based method was employed to develop QSAR models for a series of migrastatin and isomigrastatin analogs. Significant correlation coefficients were obtained (best model, q2 = 0.76 and r2 = 0.91) indicating that the QSAR models possess high internal consistency. The best model was then used to predict the potency of an external test set, and the predicted values were in good agreement with the experimental results (R2pred = 0.85). The final model and the corresponding contribution maps, combined with molecular modeling studies, provided important insights into the key structural features for the anticancer activity of this family of synthetic compounds based on natural products.
Keywords: Cancer, metastasis, QSAR, drug design, migrastatin, macrolide, inhibitors, invasion, migration, isomigrastatin analogs, correlation coefficients, anticancer activity
Medicinal Chemistry
Title: Quantitative Structure-Activity Studies on a Series of Migrastatin Analogs as Inhibitors of Cancer Cell Metastasis
Volume: 7 Issue: 3
Author(s): Ricardo N. Santos, Rafael V. C. Guido, Glaucius Oliva, Luiz C. Dias and Adriano D. Andricopulo
Affiliation:
Keywords: Cancer, metastasis, QSAR, drug design, migrastatin, macrolide, inhibitors, invasion, migration, isomigrastatin analogs, correlation coefficients, anticancer activity
Abstract: Migrastatin, a macrolide natural product, and its structurally related analogs are potent inhibitors of cancer cell metastasis, invasion and migration. In the present work, a specialized fragment-based method was employed to develop QSAR models for a series of migrastatin and isomigrastatin analogs. Significant correlation coefficients were obtained (best model, q2 = 0.76 and r2 = 0.91) indicating that the QSAR models possess high internal consistency. The best model was then used to predict the potency of an external test set, and the predicted values were in good agreement with the experimental results (R2pred = 0.85). The final model and the corresponding contribution maps, combined with molecular modeling studies, provided important insights into the key structural features for the anticancer activity of this family of synthetic compounds based on natural products.
Export Options
About this article
Cite this article as:
N. Santos Ricardo, V. C. Guido Rafael, Oliva Glaucius, C. Dias Luiz and D. Andricopulo Adriano, Quantitative Structure-Activity Studies on a Series of Migrastatin Analogs as Inhibitors of Cancer Cell Metastasis, Medicinal Chemistry 2011; 7 (3) . https://dx.doi.org/10.2174/157340611795564240
DOI https://dx.doi.org/10.2174/157340611795564240 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Towards Multifunctional Synthetic Vectors
Current Gene Therapy Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues
Current Medicinal Chemistry Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Electrochemical Nano-biosensors as Novel Approach for the Detection of Lung Cancer-related MicroRNAs
Current Molecular Medicine Patents in Cancer Stem Cells
Recent Patents on Biomarkers Cytokines in Colitis-Associated Cancer: Potential Drug Targets?
Inflammation & Allergy - Drug Targets (Discontinued) Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities
Anti-Cancer Agents in Medicinal Chemistry Adipocytes Contribute to Resistance of Human Melanoma Cells to Chemotherapy and Targeted Therapy
Current Medicinal Chemistry Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues
Current Diabetes Reviews Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine